These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 15538829)

  • 1. In-vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts.
    Quindós G; Ruesga MT; Martín-Mazuelos E; Salesa R; Alonso-Vargas R; Carrillo-Muñoz AJ; Brena S; San Millán R; Pontón J
    Rev Iberoam Micol; 2004 Jun; 21(2):63-9. PubMed ID: 15538829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Determination of the in vitro antifungal susceptibility of clinically important yeasts using the Sensititre system].
    Carrillo-Muñoz AJ; Quindós G; Gasser I; Tur-Tur C; Ruesga MT; Alonso-Vargas R; Arévalo P; Bornay-Llinares FJ; Santos P; del Valle O
    Rev Esp Quimioter; 1999 Jun; 12(2):126-35. PubMed ID: 10562673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal activity of phenylheptatriyne from Bidens cernua L. against yeasts.
    Rybalchenko NP; Prykhodko VA; Nagorna SS; Volynets NN; Ostapchuk AN; Klochko VV; Rybalchenko TV; Avdeeva LV
    Fitoterapia; 2010 Jul; 81(5):336-8. PubMed ID: 19837144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flucytosine primary resistance in Candida species and Cryptococcus neoformans.
    Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Rodríguez-Tudela JL
    Eur J Clin Microbiol Infect Dis; 2001 Apr; 20(4):276-9. PubMed ID: 11399020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular epidemiology and antifungal susceptibility of Candida species isolated from urine samples of patients in intensive care unit].
    Yüksekkaya S; Fındık D; Arslan U
    Mikrobiyol Bul; 2011 Jan; 45(1):137-49. PubMed ID: 21341168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
    Ozcan SK; Mutlu B; Dündar D; Willke A
    Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
    Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
    J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activity of posaconazole against yeasts isolated in blood cultures].
    Cantón E; Pemán J; Orero A; Viudes A; Gil J; Rubio MC; Gobernado M
    Rev Esp Quimioter; 2002 Dec; 15(4):335-40. PubMed ID: 12587038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.
    Pfaller MA; Messer SA; Boyken L; Huynh H; Hollis RJ; Diekema DJ
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3518-21. PubMed ID: 12384359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts.
    Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K
    Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2006 Oct; 44(10):3533-8. PubMed ID: 17021079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.
    Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period.
    Kucukates E; Erturan Z; Susever S; Yegenoglu Y
    APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
    Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method.
    Pfaller MA; Barry AL
    Mycopathologia; 1995; 130(1):3-9. PubMed ID: 7666925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts.
    Ryder NS; Wagner S; Leitner I
    Antimicrob Agents Chemother; 1998 May; 42(5):1057-61. PubMed ID: 9593126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
    Fleck R; Dietz A; Hof H
    J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro activities of posaconazole, fluconazole, itraconazole, ketoconazole and voriconazole against Candida glabrata].
    Blanco MT; Cañadas J; García-Martos P; Marín P; García-Tapia A; Rodríguez J
    Rev Esp Quimioter; 2009 Sep; 22(3):139-43. PubMed ID: 19662547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.